1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
Delayed Australian Stock Exchange  -  05/25 02:10:52 am EDT
273.60 AUD   -0.20%
05/23Australian shares subdued as tech, healthcare offset mining gains
RE
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
05/11Australian shares rise on healthcare, mining boost; U.S. inflation data in focus
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CSL drags Australian shares lower, tech stocks rise

12/15/2021 | 07:36pm EDT

Dec 16 (Reuters) - Australian shares inched lower on Thursday, as index heavyweight CSL led healthcare stocks lower following a discounted equity raising while tech heavyweights tracked their U.S. peers higher.

The S&P/ASX 200 index fell 0.1% to 7,313.4 by 2358 GMT, down for a third straight session.

Shares of CSL dropped as much as 8.8% to A$271.14 and were on track for their worst session since March 23, 2020 as trading resumed after a two-day trading halt.

CSL, the country's fourth-biggest company by market value, completed a A$6.3 billion ($4.52 billion) equity raise to fund its $11.7 billion Vifor Pharma AG deal. The issue price represented an 8.2% discount to Monday's close.

Healthcare stocks fell 5.1% and were headed for their worst session since March 2020.

Tech stocks rose 2%, set for their best session in more than a year, tracking the Nasdaq's strong finish overnight after the U.S. Federal Reserve said it would end its pandemic-era bond purchases in March amid rising inflation.

Wisetech Global climbed 4.6% to lead gains on the sub-index, while sector major Afterpay was up 3.4%.

Financials were up 0.5%, with the big four banks gaining between 0.1% and 0.9%

In other major corporate news, Qantas flagged a first-half loss owing to months of lockdowns. Its shares fell 2.1% and extended losses to a seventh session.

Across the Tasman Sea, New Zealand's benchmark stock index fell 0.2% to 12,847.59. The country's gross domestic product shrank 3.7% in the third quarter from the previous quarter, the second largest decline on record, as the economy was hit by an outbreak of the Delta variant of COVID-19. ($1 = 1.3943 Australian dollars) (Reporting by Tejaswi Marthi in Bengaluru; Editing by Subhranshu Sahu)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AFTERPAY -2.18% 66.47 End-of-day quote.-19.93%
CSL LIMITED -0.20% 273.6 Delayed Quote.-5.70%
QANTAS AIRWAYS LIMITED -0.56% 5.35 Delayed Quote.7.39%
S&P/ASX 200 0.37% 7155.2 Real-time Quote.-4.24%
VIFOR PHARMA AG -1.80% 169.5 Delayed Quote.6.38%
WISETECH GLOBAL LIMITED -3.23% 39.86 Delayed Quote.-29.69%
All news about CSL LIMITED
05/23Australian shares subdued as tech, healthcare offset mining gains
RE
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
05/11Australian shares rise on healthcare, mining boost; U.S. inflation data in focus
RE
05/06Australia shares slump as inflation woes hint at more rate hikes
RE
04/20CSL Prices $4 Billion of Bonds in US Debt Market
MT
04/20PAUL RAMSAY : KKR-led group offers record $14.8 billion bid for Australia's Ramsay Health
RE
03/31Australia shares inch lower on tech, energy losses
RE
03/29CSL Behring - European Medicines Agency Commences Review of Novel Gene Therapy Candidat..
AQ
03/28Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Q..
AQ
03/23CSL BEHRING AG - PUBLICATION OF PROV : Participation rate of 94 percent
AQ
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Financials (USD)
Sales 2022 10 734 M - -
Net income 2022 2 273 M - -
Net Debt 2022 7 484 M - -
P/E ratio 2022 39,8x
Yield 2022 1,07%
Capitalization 93 252 M 93 252 M -
EV / Sales 2022 9,38x
EV / Sales 2023 7,59x
Nbr of Employees 25 000
Free-Float 95,0%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 193,58 $
Average target price 223,45 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Mark Hill Chief Digital Information Officer
Sector and Competitors
1st jan.Capi. (M$)
CSL LIMITED-5.70%93 360
SAMSUNG BIOLOGICS CO.,LTD.-7.97%45 499
BIOGEN INC.-15.58%29 662
WUXI BIOLOGICS (CAYMAN) INC.-42.63%28 538
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.05%21 450
UCB-17.33%16 839